Walleye Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$16.5M Sell
87,365
-28,393
-25% -$4.96M 0.07% 244
2025
Q4
$19.7M Buy
115,758
+32,964
+40% +$5.05M 0.06% 307
2025
Q3
$10.9M Buy
+82,794
New +$9.93M 0.04% 504
2024
Q3
Sell
-10,071
Closed -$1.07M 5580
2024
Q2
$1.07M Buy
10,071
+5,840
+138% +$642K ﹤0.01% 2770
2024
Q1
$509K Buy
+4,231
New +$518K ﹤0.01% 3176
2023
Q4
Sell
-73,883
Closed -$9.22M 5223
2023
Q3
$9.56M Sell
73,883
-24,962
-25% -$3.33M 0.02% 602
2023
Q2
$12.3M Buy
98,845
+97,597
+7,820% +$13.1M 0.04% 321
2023
Q1
$183K Buy
+1,248
New +$185K ﹤0.01% 2537
2022
Q3
Sell
-18,326
Closed -$2.79M 3386
2022
Q2
$2.86M Buy
18,326
+11,323
+162% +$1.74M 0.08% 277
2022
Q1
$1.09M Sell
7,003
-884
-11% -$128K 0.03% 599
2021
Q4
$1M Buy
+7,887
New +$1.04M 0.03% 592
2020
Q1
Sell
-3,190
Closed -$476K 1300
2019
Q4
$476K Buy
3,190
+2,870
+897% +$391K 0.03% 690
2019
Q3
$41K Hold
320
﹤0.01% 1638
2019
Q2
$46K Sell
320
-2,864
-90% -$385K 0.01% 1400
2019
Q1
$456K Buy
+3,184
New +$415K 0.08% 419

Other funds holding JAZZ

Walleye Capital's JAZZ Position: Q1 2026 in Review

Walleye Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 25% in Q1 2026, selling an estimated $4.96M and leaving 87,365 shares worth $16.5M. The position accounts for 0.07% of the portfolio, ranked #244.

Walleye Capital first reported a position in JAZZ in Q1 2019 and has held it in 15 quarters since. The position peaked at $19.7M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Walleye Capital held 87,365 shares of Jazz Pharmaceuticals worth $16.5M as of Q1 2026.
  • Walleye Capital sold 28,393 Jazz Pharmaceuticals shares in Q1 2026, an estimated $4.96M.
  • Jazz Pharmaceuticals made up 0.07% of Walleye Capital's portfolio in Q1 2026, its #244 holding.
  • Walleye Capital first reported a position in Jazz Pharmaceuticals in Q1 2019 and has held it in 15 quarters since.
  • Walleye Capital's Jazz Pharmaceuticals position peaked at $19.7M in Q4 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.